JBJ-04-125-02 R-izomè
Pwodwi detay
Tags pwodwi
| Gwosè pake | Disponibilite | Pri (USD) |
Non Chimik:
(R)-2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxo-6-(4-(piperazin-1-yl)phenyl)isoindolin-2-yl)-N-(thiazol-2 -yl)acetamid
Kòd SMILES:
O=C([C@H](N(C1=O)CC2=C1C=C(C=C2)C3=CC=C(C=C3)N4CCNCC4)C5=CC(F)=CC=C5O)NC6 =NC=CS6
Kòd InChi:
InChI=1S/C29H26FN5O3S/c30-21-5-8-25(36)24(16-21)26(27(37)33-29-32-11-14-39-29)35-17-20- 2-1-19(15-23(20)28( 35)38)18-3-6-22(7-4-18)34-12-9-31-10-13-34/h1-8,11,14-16,26,31,36H,9- 10,12-13,17H2,(H,32,33,37)/t26-/m1/s1
InChi kle:
VHQVOTINPRYDAO-AREMUKBSSA-N
Mot:
Solibilite:
Depo:
Deskripsyon:
JBJ-04-125-02 se yon inibitè allosterik EGFR mutant-selektif ak potansyèl aktivite antikansè. Kòm yon ajan sèl, li ka anpeche pwopagasyon selilè ak EGFRL858R/T790M/C797S siyal in vitro ak in vivo. Konbinezon osimertinib ak JBJ-04-125-02 rezilta nan yon ogmantasyon nan apoptoz, yon anpèchman pi efikas nan kwasans selilè, ak yon efikasite ogmante nan vitro ak nan vivo konpare ak swa ajan sèl pou kont li.
Sib: EGFR
